OmniAb Inc. (NASDAQ:OABI) — Market Cap & Net Worth
Market Cap & Net Worth: OmniAb Inc. (OABI)
OmniAb Inc. (NASDAQ:OABI) has a market capitalization of $324.74 Million ($324.74 Million) as of August 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14447 globally and #3409 in its home market, demonstrating a 54.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OmniAb Inc.'s stock price $3.08 by its total outstanding shares 144972579 (144.97 Million). See OABI capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
OmniAb Inc. Market Cap History: 2021 to 2026
OmniAb Inc.'s market capitalization history from 2021 to 2026. Data shows change from $1.45 Billion to $446.52 Million (-21.15% CAGR).
Index Memberships
OmniAb Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.50 Trillion | 0.01% | #392 of 976 |
|
NASDAQ Composite
IXIC
|
$40.86 Trillion | 0.00% | #1412 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.74 Trillion | 0.02% | #208 of 263 |
Weight: OmniAb Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OmniAb Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OmniAb Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.37x
OmniAb Inc.'s market cap is 14.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.45 Billion | $34.75 Million | -$27.04 Million | 41.72x | N/A |
| 2022 | $521.90 Million | $59.08 Million | -$22.33 Million | 8.83x | N/A |
| 2023 | $894.48 Million | $34.16 Million | -$50.62 Million | 26.18x | N/A |
| 2024 | $513.20 Million | $26.39 Million | -$62.03 Million | 19.45x | N/A |
| 2025 | $268.20 Million | $18.67 Million | -$64.78 Million | 14.37x | N/A |
Competitor Companies of OABI by Market Capitalization
Companies near OmniAb Inc. in the global market cap rankings as of August 10, 2026.
Key companies related to OmniAb Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #555 globally with a market cap of $48.81 Billion USD ( ₩72.03 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $496.07 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $784.36 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €763.20 |
| #555 | Samsung Biologics Co Ltd | KO:207940 | $48.81 Billion | ₩1556000.00 |
OmniAb Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, OmniAb Inc.'s market cap moved from $1.45 Billion to $ 446.52 Million, with a yearly change of -21.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $446.52 Million | +66.49% |
| 2025 | $268.20 Million | -47.74% |
| 2024 | $513.20 Million | -42.63% |
| 2023 | $894.48 Million | +71.39% |
| 2022 | $521.90 Million | -64.00% |
| 2021 | $1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 9th, 2026 the market cap of OmniAb Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $324.74 Million USD |
| MoneyControl | $324.74 Million USD |
| MarketWatch | $324.74 Million USD |
| marketcap.company | $324.74 Million USD |
| Reuters | $324.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more